NovoCure (NASDAQ:NVCR) & Innovative Eyewear (NASDAQ:LUCYW) Head-To-Head Survey

Innovative Eyewear (NASDAQ:LUCYW) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

84.6% of NovoCure shares are held by institutional investors. 6.6% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Innovative Eyewear and NovoCure”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.98 million	N/A	N/A	N/A	N/A
NovoCure	$699.19 million	2.73	-$136.23 million	($1.30)	-12.61

Innovative Eyewear has higher earnings, but lower revenue than NovoCure.

Profitability

This table compares Innovative Eyewear and NovoCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	N/A	N/A	N/A
NovoCure	-21.25%	-44.00%	-15.85%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Innovative Eyewear and NovoCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	0	0	0	0	0.00
NovoCure	1	4	2	0	2.14

NovoCure has a consensus target price of $21.20, suggesting a potential upside of 29.35%. Given NovoCure’s stronger consensus rating and higher probable upside, analysts plainly believe NovoCure is more favorable than Innovative Eyewear.

Summary

NovoCure beats Innovative Eyewear on 6 of the 9 factors compared between the two stocks.

About Innovative Eyewear

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform various smartphone tasks hands-free. It also offers smart eyewear under the Lyte XL brand; and Nautica Powered by Lucyd smart eyewear collection and various branded accessories, including a power brick, cleaning cloth, and a slipcase adorned. In addition, the company provides Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with an individual's voice; and Lucyd app for iOS and Android to provide voice access to ChatGPT in Lucyd eyewear. It sells its products through various e-commerce and retail channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.